Literature DB >> 1924152

Synthesis of the enantiomers of reduced haloperidol.

J C Jaen1, B W Caprathe, S Priebe, L D Wise.   

Abstract

Reduced haloperidol (RHAL) is the best known metabolite of haloperidol (HAL), having been identified in humans, rats, and guinea pigs. Since RHAL contains an asymmetric center, it can exist in two possible enantiomeric forms. However, the enantiomeric composition of the RHAL formed from HAL in vivo has never been reported. As a first step toward the enantiomeric analysis of biological samples, we have developed an efficient and stereospecific synthesis of (+)- and (-)-RHAL from readily available commercial materials. We have also identified an enantioselective chromatographic method using a chiral HPLC stationary phase which can detect as little as 1% of either enantiomer in synthetic samples of RHAL enantiomers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924152     DOI: 10.1023/a:1015800923078

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.

Authors:  T G Heffner; D A Downs; L T Meltzer; J N Wiley; A E Williams
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

2.  Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.

Authors:  W H Chang; T Y Chen; C F Lee; W H Hu; E K Yeh
Journal:  Biol Psychiatry       Date:  1987-11       Impact factor: 13.382

3.  Isolation and identification of a metabolite of haloperidol.

Authors:  B E Pape
Journal:  J Anal Toxicol       Date:  1981 May-Jun       Impact factor: 3.367

4.  Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors.

Authors:  W D Bowen; E L Moses; P J Tolentino; J M Walker
Journal:  Eur J Pharmacol       Date:  1990-02-27       Impact factor: 4.432

5.  Development of acute dystonia and tardive dyskinesia in cebus monkeys.

Authors:  S Bárány; A Ingvast; L M Gunne
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-08

6.  An improved sensitive assay for simultaneous determination of plasma haloperidol and reduced haloperidol levels by liquid chromatography using a coulometric detector.

Authors:  M Hariharan; E K Kindt; T VanNoord; R Tandon
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681

7.  Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.

Authors:  E R Korpi; J E Kleinman; D T Costakos; M Linnoila; R J Wyatt
Journal:  Psychiatry Res       Date:  1984-03       Impact factor: 3.222

8.  Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.

Authors:  L Ereshefsky; C M Davis; C A Harrington; M W Jann; J L Browning; S R Saklad; N R Burch
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

9.  Factors affecting the clinical response to haloperidol therapy in schizophrenia.

Authors:  S R Bareggi; M Mauri; R Cavallaro; M G Regazzetti; A R Moro
Journal:  Clin Neuropharmacol       Date:  1990       Impact factor: 1.592

10.  Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat.

Authors:  E R Korpi; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more
  2 in total

1.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

2.  Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.

Authors:  Carla Barbaraci; Giovanni Giurdanella; Claudia Giovanna Leotta; Anna Longo; Emanuele Amata; Maria Dichiara; Lorella Pasquinucci; Rita Turnaturi; Orazio Prezzavento; Ivana Cacciatore; Elisa Zuccarello; Gabriella Lupo; Giovanni Mario Pitari; Carmelina Daniela Anfuso; Agostino Marrazzo
Journal:  J Med Chem       Date:  2021-09-03       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.